Want to join the conversation?
$PFE announces positive top-line results of two Phase 3 studies of oral tofacitinib (XELJANZ) for the treatment of ulcerative colitis. Both studies, OCTAVE Induction 1 and OCTAVE Induction 2, achieved their primary endpoints measured by the proportion of patients in remission at week 8 versus placebo.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.